TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Vivesto AB ( (SE:VIVE) ) is now available.
Vivesto AB has announced the appointment of its Nomination Committee for the 2026 Annual General Meeting, following the ownership structure as of September 30, 2025. The committee consists of Per Arwidsson, Christer Hasslebäck, and Peter Zonabend, with Arwidsson as Chairman. The AGM is scheduled for May 7, 2026, in Stockholm, and shareholders are invited to submit proposals by January 31, 2026.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on creating new treatment options for hard-to-treat cancers, addressing significant medical needs and market potential. Their project portfolio includes Cantrixil for blood cancer and the veterinary oncology program Paccal Vet, which is under evaluation in clinical trials for dogs and cats with specific cancers.
Average Trading Volume: 524,772
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK123.7M
Learn more about VIVE stock on TipRanks’ Stock Analysis page.